BR112013027229A2 - composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas - Google Patents

composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas

Info

Publication number
BR112013027229A2
BR112013027229A2 BR112013027229A BR112013027229A BR112013027229A2 BR 112013027229 A2 BR112013027229 A2 BR 112013027229A2 BR 112013027229 A BR112013027229 A BR 112013027229A BR 112013027229 A BR112013027229 A BR 112013027229A BR 112013027229 A2 BR112013027229 A2 BR 112013027229A2
Authority
BR
Brazil
Prior art keywords
clostridium difficile
mutant
methods
toxin
difficile toxin
Prior art date
Application number
BR112013027229A
Other languages
English (en)
Other versions
BR112013027229B1 (pt
Inventor
Annaliesa Sybil Anderson
Justin Keith Moran
Kathrin Ute Jansen
Maninder K Sidhu
Mark E Ruppen
Michael James Flint
Narender K Kalyan
Robert G K Donald
Terri L Mininni
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Priority to BR122019017005-3A priority Critical patent/BR122019017005B1/pt
Publication of BR112013027229A2 publication Critical patent/BR112013027229A2/pt
Publication of BR112013027229B1 publication Critical patent/BR112013027229B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas em um aspecto, a invenção refere-se a uma composição imunogênica que inclui uma toxina a de clostridium difficile mutante e/ou uma toxina b de clostridium difficile mutante. cada toxina mutante inclui um domínio de glucosiltransferase que possui pelo menos uma mutação e um domínio de cisteína protease que possui pelo menos uma mutação, em relação à toxina de c. difficile do tipo selvagem correspondente. as toxinas mutantes podem incluir ainda pelo menos um aminoácido que é quimicamente reticulado. em outro aspecto, a invenção refere-se a anticorpos ou fragmentos de ligação dos mesmos que se ligam às ditas composições imunogênicas. em aspectos adicionais, a invenção refere-se a sequências de nucleotídeos isoladas que codificam qualquer um do que foi descrito anteriormente e métodos de uso de qualquer uma das composições anteriores.
BR112013027229-5A 2011-04-22 2012-04-20 polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante BR112013027229B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019017005-3A BR122019017005B1 (pt) 2011-04-22 2012-04-20 Composições que se relacionam a uma toxina de clostridium difficile mutante

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US61/478,474 2011-04-22
US201161478899P 2011-04-25 2011-04-25
US61/478,899 2011-04-25
PCT/IB2012/051999 WO2012143902A1 (en) 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof

Publications (2)

Publication Number Publication Date
BR112013027229A2 true BR112013027229A2 (pt) 2016-11-29
BR112013027229B1 BR112013027229B1 (pt) 2020-10-27

Family

ID=46085103

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013027229-5A BR112013027229B1 (pt) 2011-04-22 2012-04-20 polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR122019017005-3A BR122019017005B1 (pt) 2011-04-22 2012-04-20 Composições que se relacionam a uma toxina de clostridium difficile mutante

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019017005-3A BR122019017005B1 (pt) 2011-04-22 2012-04-20 Composições que se relacionam a uma toxina de clostridium difficile mutante

Country Status (29)

Country Link
US (13) US8481692B2 (pt)
EP (4) EP3505531B1 (pt)
JP (8) JP5917682B2 (pt)
KR (1) KR101667837B1 (pt)
CN (3) CN103619871B (pt)
AR (1) AR086199A1 (pt)
AU (6) AU2012245904B2 (pt)
BR (2) BR112013027229B1 (pt)
CA (1) CA2832712C (pt)
CO (1) CO6801643A2 (pt)
DK (2) DK3549949T5 (pt)
ES (3) ES2968629T3 (pt)
FI (1) FI3549949T3 (pt)
HR (2) HRP20231631T1 (pt)
HU (2) HUE047085T2 (pt)
IL (8) IL270779B2 (pt)
MX (1) MX347521B (pt)
MY (2) MY168205A (pt)
NZ (1) NZ616035A (pt)
PE (2) PE20141029A1 (pt)
PL (3) PL3549949T3 (pt)
PT (2) PT3549949T (pt)
RU (2) RU2754446C2 (pt)
SA (3) SA115360697B1 (pt)
SG (3) SG10201911993UA (pt)
SI (3) SI3549949T1 (pt)
TW (6) TWI701257B (pt)
WO (1) WO2012143902A1 (pt)
ZA (1) ZA201307818B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007280861B2 (en) * 2006-08-02 2013-02-07 Johannes Gutenberg-Universitat Mainz Medicament for LCT poisoning
BRPI0923341B8 (pt) * 2008-12-09 2021-05-25 Coley Pharm Group Inc oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
EP2753352B2 (en) * 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2916866B1 (de) * 2012-11-06 2018-04-04 Bayer Pharma Aktiengesellschaft Formulierung für bispecific t-cell-engangers (bites)
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
EP2968508B1 (en) 2013-03-15 2022-04-27 Sanofi Pasteur Biologics, LLC Antibodies against clostridium difficile toxins and methods of using the same
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
US11434264B2 (en) * 2015-02-13 2022-09-06 Quanterix Corporation Immunoassays for differential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
MY196869A (en) 2016-06-27 2023-05-05 Univ California Cancer treatment combinations
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
US20200254081A1 (en) * 2017-09-28 2020-08-13 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2020201985A1 (en) * 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
EP3965810A4 (en) * 2019-05-10 2023-01-25 The Board Of Regents Of The University Of Oklahoma CLOSTRIDIOIDES DIFFICILE TCDB VARIANTS, VACCINES AND METHOD OF USE
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
CN115697330A (zh) * 2020-05-06 2023-02-03 阿尔伯特·爱因斯坦医学院 通过抑制肠道损伤性细菌毒素TcdA和TcdB预防来自艰难梭菌感染的组织损伤的活性剂
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
AU2023235562A1 (en) 2022-03-14 2024-08-22 Pfizer Inc. Methods for producing an adjuvant
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024127215A2 (en) 2022-12-13 2024-06-20 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
ES2113428T3 (es) 1991-04-22 1998-05-01 Massachusetts Health Res Proceso de tamizado de muestras de plasma para determinar titulos de anticuerpos efectivos contra los virus respiratorios.
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
JP4129544B2 (ja) 1993-03-29 2008-08-06 ファイザー・インク サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
WO1996007430A1 (en) 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
AU709586B2 (en) * 1994-10-24 1999-09-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
NZ312876A (en) 1995-07-07 2000-06-23 Oravax Inc Intranasal, muscosal and systemic vaccination against C. difficile inducing a mucosal immune response in the gastrointestinal and/or genitourinary tracts
JPH11509200A (ja) 1995-07-07 1999-08-17 オラバックス インク． 粘膜アジュバントとしてのクロストリジウム・ディフィシール（Ｃｌｏｓｔｒｉｄｉｕｍ Ｄｉｆｆｉｃｉｌｅ）トキシン
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
AU7362096A (en) 1995-09-15 1997-04-01 Dale N. Gerding M.D. Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
JP4224136B2 (ja) 1996-07-12 2009-02-12 ファースト オピニオン コーポレーション リストベース処理を用いたコンピュータ化医療診断システム
EA199900342A1 (ru) 1996-09-30 1999-10-28 Эмбрекс, Инк. Способ создания активного иммунитета вакцинным конъюгатом
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU781175B2 (en) 1999-04-09 2005-05-12 Intercell Usa, Inc. Recombinant toxin A/toxin B vaccine against Clostridium Difficile
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
AU2001261171A1 (en) * 2000-05-04 2001-11-12 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
EP1601689B1 (en) * 2003-03-13 2007-11-28 GlaxoSmithKline Biologicals S.A. Purification process for bacterial cytolysin
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
ES2707786T3 (es) 2004-01-16 2019-04-05 Pfenex Inc Expresión de proteínas de mamífero en Pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
RS51908B (en) * 2004-02-06 2012-02-29 University Of Massachusetts CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1833510A4 (en) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
WO2007090126A2 (en) * 2006-01-30 2007-08-09 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
AU2007245198B2 (en) * 2006-03-30 2010-08-12 Zoetis Services Llc Methods and compositions for vaccination of poultry
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
ES2524556T3 (es) 2006-10-09 2014-12-10 Charleston Laboratories, Inc. Composiciones farmacéuticas
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
CN101617362B (zh) * 2007-03-02 2012-07-18 松下电器产业株式会社 语音解码装置和语音解码方法
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
SI2198007T1 (en) * 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
WO2009139919A2 (en) 2008-05-15 2009-11-19 Tufts University Methods for diagnosis of clostridium diffcile and methods and vectors for recombinant toxin expression
CA2729248A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US9115347B2 (en) 2008-09-24 2015-08-25 Sanofi Pasteur Biologies, LLC Methods and compositions for increasing toxin production
US8444996B2 (en) 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2373332A1 (en) 2008-12-03 2011-10-12 Boehringer Ingelheim Vetmedica GmbH Process for production of vaccines
BRPI0923341B8 (pt) 2008-12-09 2021-05-25 Coley Pharm Group Inc oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
JP5740714B2 (ja) * 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
EP2470664A4 (en) * 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
EP2753352B2 (en) * 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US20120129715A1 (en) * 2010-11-12 2012-05-24 Sidhu Sachdev S Gb1 peptidic libraries and methods of screening the same
BR112013027229B1 (pt) * 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
SI2714911T1 (sl) 2011-05-27 2017-03-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
WO2012166991A1 (en) * 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
ES2704069T3 (es) * 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112015004629A2 (pt) 2012-09-19 2017-11-21 Novartis Ag polipeptídeos de clostridium difficile como vacinas
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP2016501877A (ja) 2012-11-28 2016-01-21 シーエヌジェー ホールディングス，インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
FI3513806T3 (fi) 2012-12-05 2023-04-26 Glaxosmithkline Biologicals Sa Immunogeeninen koostumus
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
AU2014228956A1 (en) 2013-03-15 2015-10-08 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
EP2968508B1 (en) 2013-03-15 2022-04-27 Sanofi Pasteur Biologics, LLC Antibodies against clostridium difficile toxins and methods of using the same
EP2981611A4 (en) 2013-04-02 2016-11-16 Stc Unm ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
WO2015061529A1 (en) 2013-10-23 2015-04-30 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2017085602A1 (en) 2015-11-17 2017-05-26 Pfizer Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
JP7149285B2 (ja) 2017-03-15 2022-10-06 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
US20200254081A1 (en) 2017-09-28 2020-08-13 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
US9187536B1 (en) 2015-11-17
US10774117B2 (en) 2020-09-15
AU2018201296A1 (en) 2018-03-15
USRE46518E1 (en) 2017-08-22
KR20130140206A (ko) 2013-12-23
CN103619871B (zh) 2016-12-14
JP2014514318A (ja) 2014-06-19
TW201302780A (zh) 2013-01-16
IL270779A (en) 2020-01-30
AU2016202903B2 (en) 2017-11-30
CA2832712A1 (en) 2012-10-26
SA112330472B1 (ar) 2015-11-02
JP6735784B2 (ja) 2020-08-05
FI3549949T3 (fi) 2024-01-30
SG10201602668VA (en) 2016-05-30
PT2699587T (pt) 2019-09-05
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
MY182429A (en) 2021-01-25
MY168205A (en) 2018-10-15
US20120269841A1 (en) 2012-10-25
USRE48863E1 (en) 2021-12-28
EP3505531A1 (en) 2019-07-03
US20200095290A1 (en) 2020-03-26
JP6892425B2 (ja) 2021-06-23
PL3549949T3 (pl) 2024-04-08
AU2017261465B2 (en) 2018-10-04
PL2699587T3 (pl) 2019-12-31
RU2592686C2 (ru) 2016-07-27
SA115360698B1 (ar) 2016-04-27
JP5917682B2 (ja) 2016-05-18
IL254440B (en) 2019-12-31
JP6321239B2 (ja) 2018-05-09
CN103619871A (zh) 2014-03-05
PE20141029A1 (es) 2014-09-04
IL254418A0 (en) 2017-11-30
MX2013012344A (es) 2013-11-20
AU2020230248A1 (en) 2020-10-01
US20150307563A1 (en) 2015-10-29
TWI701257B (zh) 2020-08-11
JP2018135345A (ja) 2018-08-30
SI2699587T1 (sl) 2019-08-30
IL265510B (en) 2021-05-31
US20150125927A1 (en) 2015-05-07
US10597428B2 (en) 2020-03-24
SI3505531T1 (sl) 2024-02-29
JP2017125030A (ja) 2017-07-20
DK3549949T3 (da) 2023-12-18
IL273231B (en) 2021-08-31
PL3505531T3 (pl) 2024-03-11
RU2015154443A3 (pt) 2019-05-22
IL273231A (en) 2020-04-30
EP4365196A3 (en) 2024-08-07
TWI671313B (zh) 2019-09-11
CO6801643A2 (es) 2013-11-29
EP3549949B1 (en) 2023-11-29
CN107022532A (zh) 2017-08-08
IL228944A0 (en) 2013-12-31
DK3549949T5 (da) 2024-09-02
JP2016117745A (ja) 2016-06-30
IL255345A0 (en) 2017-12-31
DK2699587T3 (da) 2019-08-05
US9745354B2 (en) 2017-08-29
US20130330371A1 (en) 2013-12-12
US20230391835A1 (en) 2023-12-07
AU2016202903A1 (en) 2016-05-26
CN107022532B (zh) 2021-05-04
EP2699587A1 (en) 2014-02-26
JP2022126822A (ja) 2022-08-30
AU2019246878A1 (en) 2019-10-31
JP6097853B2 (ja) 2017-03-15
NZ616035A (en) 2016-03-31
HRP20240042T1 (hr) 2024-03-29
US20170313749A1 (en) 2017-11-02
AR086199A1 (es) 2013-11-27
JP2018052938A (ja) 2018-04-05
US11535652B2 (en) 2022-12-27
TWI650329B (zh) 2019-02-11
HUE047085T2 (hu) 2020-04-28
TW202320843A (zh) 2023-06-01
BR122019017005B1 (pt) 2022-03-29
US8900597B2 (en) 2014-12-02
ES2968629T3 (es) 2024-05-13
US8557548B2 (en) 2013-10-15
IL254418B (en) 2019-12-31
US20190202873A1 (en) 2019-07-04
RU2013145170A (ru) 2015-06-27
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
CA2832712C (en) 2018-08-28
TW201932481A (zh) 2019-08-16
AU2012245904A1 (en) 2013-10-17
EP3505531B1 (en) 2023-11-15
IL265510A (en) 2019-05-30
TW201932480A (zh) 2019-08-16
AU2020230248B2 (en) 2022-12-01
CN111647059A (zh) 2020-09-11
ES2742823T3 (es) 2020-02-17
ES2969952T3 (es) 2024-05-23
US20130244307A1 (en) 2013-09-19
IL255345B (en) 2021-05-31
EP3549949A1 (en) 2019-10-09
TWI804717B (zh) 2023-06-11
AU2017261465A1 (en) 2017-11-30
JP2019052149A (ja) 2019-04-04
ZA201307818B (en) 2014-06-25
KR101667837B1 (ko) 2016-10-20
RU2754446C2 (ru) 2021-09-02
AU2019246878B2 (en) 2020-09-10
EP2699587B1 (en) 2019-07-03
SG194132A1 (en) 2013-11-29
JP7097478B2 (ja) 2022-07-07
BR112013027229B1 (pt) 2020-10-27
RU2015154443A (ru) 2019-01-17
TWI815599B (zh) 2023-09-11
SA115360697B1 (ar) 2016-04-05
PT3549949T (pt) 2024-02-02
PE20181334A1 (es) 2018-08-21
IL228944A (en) 2017-11-30
AU2012245904B2 (en) 2016-04-21
HUE065594T2 (hu) 2024-06-28
US8481692B2 (en) 2013-07-09
HRP20231631T1 (hr) 2024-03-15
USRE48862E1 (en) 2021-12-28
CN111647059B (zh) 2023-11-28
SG10201911993UA (en) 2020-02-27
IL245047A0 (en) 2016-05-31
WO2012143902A1 (en) 2012-10-26
MX347521B (es) 2017-04-27
EP4365196A2 (en) 2024-05-08
JP2021130692A (ja) 2021-09-09
TW202041525A (zh) 2020-11-16
IL270779B2 (en) 2024-09-01
TW201806967A (zh) 2018-03-01
USRE46376E1 (en) 2017-04-25

Similar Documents

Publication Publication Date Title
BR112013027229A2 (pt) composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas
BR112015008844A8 (pt) composições e métodos relacionados a uma toxina de clostridium difficile mutante
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
BR112014008529A2 (pt) il-6 humanizado e receptor de il-6
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112014017165A8 (pt) polipeptídeos de fator quimérico viii e seus usos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112016007255A2 (pt) polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CR20110035A (es) Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
BR112015013004A2 (pt) molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo
BR112016014405A2 (pt) cepa mutante atenuada de salmonela
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
BR112012010266A2 (pt) anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: WYETH LLC (US)